HealthDay News — Thirty-day mortality is lower for hospitalization with acute myocardial infarction (MI) during Transcatheter Cardiovascular Therapeutics meeting dates, according to a study published online in the Journal of the American Heart Association.
Anupam B. Jena, MD, PhD, from Harvard Medical School in Boston, and colleagues analyzed 30-day mortality in Medicare beneficiaries hospitalized with acute MI from January 1, 2007, to November 31, 2012, in major teaching hospitals. Mortality was compared during dates of a major annual interventional cardiology meeting (Transcatheter Cardiovascular Therapeutics) vs identical nonmeeting days in the 5 weeks before and after.
The researchers found that patients admitted during meeting vs nonmeeting dates had lower unadjusted and adjusted 30-day mortality rates (unadjusted: 15.3% vs 16.7%; P =.04; adjusted: 15.4% vs 16.7%; P =.05). Between the dates, the rates of interventional cardiologist involvement were similar (59.5% vs 59.8% of hospitalizations; P =.88), as were rates of percutaneous coronary intervention (30.2% vs 29.1%; P =.20). Patients with non-ST-segment-elevation MI not receiving percutaneous coronary intervention had the largest mortality reductions (16.9% vs 19.5% adjusted 30-day mortality; P =.008).
“Hospitalization with acute myocardial infarction during Transcatheter Cardiovascular Therapeutics meeting dates was associated with lower 30-day mortality, predominantly among patients with non-ST-segment-elevation myocardial infarction who were medically managed,” the authors wrote.
Disclosures: One author disclosed financial ties to the pharmaceutical industry; two authors disclosed ties to Precision Health Economics.
Jena AM, Olenski A, Blumenthal DM, et al. Acute myocardial infarction mortality during dates of national interventional cardiology meetings [published online March 9, 2018]. J Am Heart Assoc. doi:10.1161/JAHA.117.008230